Donitriptan
≈ 2 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Donitriptan ( ; developmental code name F-11356) is a triptan drug which was investigated as an antimigraine agent but was never marketed. It acts as a selective serotonin 5-HT 1B and 5-HT 1D receptor agonist. The drug reached phase 2 clinical trials prior to the discontinuation of its development.
Donitriptan ( ; developmental code name F-11356) is a triptan drug which was investigated as an antimigraine agent but was never marketed. It acts as a selective serotonin 5-HT 1B and 5-HT 1D receptor agonist. The drug reached phase 2 clinical trials prior to the discontinuation of its development. ==Pharmacology== Donitriptan acts as a high-affinity, high-efficacy near-full agonist of the serotonin 5-HT 1B (K i = 0.079–0.40 nM; = 94%) and 5-HT 1D receptors (K i = 0.063–0.50 nM; = 97%), and is among the most potent of the triptan series of drugs. It is also notable and unique among most of the triptans in being a potent serotonin 5-HT 2A receptor agonist ( = 7.9 nM), albeit with about one or two orders of magnitude lower activational potency than at the serotonin 5-HT 1B and 5-HT 1D receptors. ==Chemistry== Donitriptan is a tryptamine derivative, a 5-substituted derivative of tryptamine and 5-methoxytryptamine, and an analogue of the psychedelic drugs dimethyltryptamine (DMT) and 5-MeO-DMT. The predicted log P of donitriptan is 1.32 to 2.2. ==History== Donitriptan was being developed in France by bioMérieux-Pierre Fabre and made it to phase II clinical trials in Europe before development was discontinued. ==See also== Triptan Avitriptan ==References==
Text derived from https://en.wikipedia.org/w/index.php?oldid=1341436455 under CC BY-SA 4.0; modifications have been made.